Artículos de revistas
Significance of topoisomerase III beta expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis
Fecha
2010Registro en:
HUMAN PATHOLOGY, v.41, n.11, p.1624-1630, 2010
0046-8177
10.1016/j.humpath.2010.01.027
Autor
OLIVEIRA-COSTA, Joao Paulo
ZANETTI, Juliana
OLIVEIRA, Lucinei Roberto
SOARES, Fernando Augusto
RAMALHO, Leandra Zambelli
RAMALHO, Fernando Silva
GARCIA, Sergio Britto
RIBEIRO-SILVA, Alfredo
Institución
Resumen
Topoisomerases are ubiquitous nuclear enzymes that regulate DNA structure in eukaryotic cells. The role of topoisomerase III beta, the newest member of the topoisomerase family, in the clinical outcome of breast cancer is still poorly understood. This study aims to investigate the immunoexpression of topoisomerase III beta in breast cancer and its relationships with clinicopathologic features and immunohistochemical markers of prognostic significance in breast pathology. Using tissue microarrays containing 171 cases of primary invasive breast cancer, we analyzed the immunoexpression of topoisomerase III beta, estrogen receptor, progesterone receptor, HER-2, BRCA-1, p53, and Ki67. Immunostaining for topoisomerase III beta was found in 33.9% of breast carcinomas, and immunopositivity was correlated with distant metastasis (P = .036) and death (P = .006). Decreased expression of topoisomerase III beta correlated with low expression of Ki67 (P < .001) and negativity for HER-2 (P < .001), BRCA-1 (P = .001), and p53 (P < .001). In the multivariate analysis, topoisomerase Hip expression was a significant predictor of survival (hazard ratio, 3.006 [95% confidence interval, 1.582-5.715]; P = .001). In conclusion, topoisomerase III beta expression can be a useful marker in assessing the prognosis of patients with breast cancer and is an independent predictor of survival. (C) 2010 Elsevier Inc. All rights reserved.